ABVC BIOPHARMA, INC. (ABVC)
CIK 1173313 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 26.7M shares as of Aug 10, 2026 (10-Q). Share count fell from 213.9M to 17.7M between Apr 8, 2019 and May 20, 2019, a pattern consistent with a reverse split (roughly 1-for-12); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| New Warrants | 1.0M | not tagged | — | — |
| Warrant | 398,000 | $2 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 18, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 398,000 underlying shares, as reported Jan 31, 2026 (10-Q).
Reported exercise price: $1 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $0 as of Sep 30, 2015.
Rough fully diluted estimate: 27.1M = 26.7M O/S + 398,000 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Other Convertible Notes Payable | not tagged | $150,000 | $1 | — | — |
| Other Note | not tagged | — | $5 | 0% | — |
| Other Note One | not tagged | — | $5 | 0% | — |
| Other Note Two | not tagged | — | $5 | 0% | — |
| Other Note Three | not tagged | — | $7.5 | 20% | — |
| Other Note Four | not tagged | — | $7.5 | 20% | — |
| Other Note Five | not tagged | — | $7.5 | 20% | — |
| Convertible Note Related Party | not tagged | — | $7.5 | 20% | — |
| Convertible Note Related Party One | not tagged | — | $7.5 | 20% | — |
Notes exactly as the company dimensioned them in its 10-Q filed Aug 12, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 26.7M | Aug 10, 2026 |
| + New Warrants (if exercised) | 1.0M | May 22, 2024 |
| + Warrant (if exercised) | 398,000 | Mar 31, 2026 |
| Fully diluted estimate | 28.1M | +5.2% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 9 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ABVC workspace